New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 18, 2014
07:40 EDTAGN, SHPG, VRXAllergan likely to bid for Shire, says SunTrust
SunTrust believes that Allergan (AGN) will soon bid for Shire (SHPG), and the firm thinks that this scenario is more attractive for Allergan shareholders than the offer from Valeant (VRX), as ia Shrie acquisition wouldremove the risk of holding Valeant shares. A combination of Allergan and Shire would have several advantages, including sustainable low double digit revenue growth, a more diversified sales mix, and a preservation of high value R&D programs, according to the firm. It thinks the deal would be 50% accretive to EPS in the first year and enable five year EPS CAGR to accelerate meaningfully. The firm keeps a $200 price target and Buy rating on Allergan.
News For AGN;VRX;SHPG From The Last 14 Days
Check below for free stories on AGN;VRX;SHPG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 11, 2014
11:34 EDTSHPGShire jumps 5% after Bloomberg report on talks with AbbVie
11:33 EDTSHPGShire, AbbVie held talks after latest raised takeover offer, Bloomberg says
Subscribe for More Information
July 10, 2014
09:40 EDTSHPGAbbVie, Shire not holding talks at this point as deadline approaches, CNBC says
AbbVie (ABBV) and Shire (SHPG) are not holding talks at this point, according to CNBC's David Faber, citing sources. Shire confirmed two days ago that it has received AbbVie's latest, raised takeover offer and that its board will meet to consider the proposal.
09:31 EDTVRXNestle acquires rights to aesthetic dermatology products in the U.S. and Canada
Subscribe for More Information
09:31 EDTVRXValeant completes filler, toxin asset sale to Galderma
Subscribe for More Information
July 9, 2014
18:31 EDTSHPG, AGN, VRXShareholders urge Allergan to make large acquisition, FT reports
Subscribe for More Information
18:21 EDTAGN, VRX, SHPGAllergan CEO seeks sizeable acquisitions, WSJ reports
Subscribe for More Information
08:19 EDTSHPGAbbVie offer may not bring Shire to negotiating table, says BMO Capital
Subscribe for More Information
07:38 EDTSHPGShire still has leverage, can get one more raise from AbbVie, Reuters contends
The selloff in shares of Shire (SHPG) and AbbVie (ABBV) yesterday following the latter's increased takeover offer suggests the market now expects a strong rebuttal from Shire, but "one plausible response" is a gently worded rejection that signals that another raised bid would be enough to secure a deal without a hostile play, contended Reuters Breakingviews columnists Neil Unmack and Robert Cyran. Shire’s board still has some leverage and can "probably extract one more increase in return for their recommendation," the authors believe. Reference Link
06:40 EDTSHPGAbbVie required to retract comments in Shire takeover battle, Reuters says
AbbVie (ABBV) has been required to take back comments made by its CEO Richard Gonzalez regarding shareholder support for its offer for Shire (SHPG), according to Reuters, citing a statement from the U.S. drugmaker. British takeover rules say that a rival is not allowed to claim support for its bid unless it has this in writing from shareholders. Reference Link
06:19 EDTAGN, VRXAllergan plans broad restructuring plan, Bloomberg says
Allergan (AGN), the pharmaceutical maker that is being chased by Valeant (VRX) and Bill Ackman’s hedge fund, will shelve unpromising pipeline medicines and revamp management incentives, according to Bloomberg, citing two people with knowledge of the matter. The sources said that the restructuring plan, which is set to be explained during Allergan's upcoming earnings announcement, will also detail companywide cost reductions including some legacy expenses. Reference Link
July 8, 2014
16:23 EDTSHPGOn The Fly: Closing Wrap
Subscribe for More Information
12:48 EDTSHPGOn The Fly: Midday Wrap
Subscribe for More Information
11:05 EDTSHPGHigh option volume stocks:
Subscribe for More Information
09:15 EDTSHPGOn The Fly: Pre-market Movers
Subscribe for More Information
09:05 EDTSHPGShire says board will meet to consider AbbVie proposal
Shire (SHPG) notes the announcement by AbbVie (ABBV) of a revised conditional non-binding proposal for a cash and share offer for Shire, comprising GBP 22.44 in cash and 0.8568 AbbVie shares per Shire share. "Shire confirms that AbbVie did not make the revised proposal to Shire before the announcement. The Board of Shire will meet to consider the proposal and a further announcement will be made in due course. Shareholders are strongly advised to take no action in relation to the AbbVie proposal. There can be no certainty that any firm offer will be made nor as to the terms on which any firm offer might be made. This statement is being made by Shire without the prior agreement or approval of AbbVie," Shire stated.
08:07 EDTSHPGShire volatility expected to move on AbbVie increasing proposal
Shire (SHPG) volatility is expected to move on AbbVie (ABBV) announcing that it has increased its proposal to GBP 22.44 in cash and 0.8568 ordinary shares of new AbbVie for each Shire share. This new proposal is an approximately 11% increase from AbbVie's prior indicative proposal. Overall option implied volatility of 49 is above its 26-week average of 34 according to Track Data, suggesting large near term price movement.
07:55 EDTSHPGAbbVie increases proposal for Shire to GBP 51.15 per share
Subscribe for More Information
07:54 EDTSHPGShire jumps 3% to $244 after AbbVie ups buyout offer for fourth time
07:53 EDTSHPGAbbVie raises offer for Shire to 51.15 pounds per share
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use